TherapeuticsMD, Inc. (TXMD)
USD 1.03
(4.06%)
USD 1.03
(4.06%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -10.27 Million USD | -109.18% |
| 2022 | 111.99 Million USD | 154.47% |
| 2021 | -205.6 Million USD | 3.34% |
| 2020 | -212.7 Million USD | -8.51% |
| 2019 | -196.02 Million USD | -47.81% |
| 2018 | -132.61 Million USD | -72.4% |
| 2017 | -76.92 Million USD | 14.41% |
| 2016 | -89.87 Million USD | -5.64% |
| 2015 | -85.07 Million USD | -56.92% |
| 2014 | -54.21 Million USD | -90.78% |
| 2013 | -28.41 Million USD | 19.08% |
| 2012 | -35.12 Million USD | -171.97% |
| 2011 | -12.91 Million USD | -1757.04% |
| 2010 | -695.37 Thousand USD | 57.97% |
| 2009 | -1.65 Million USD | -318.29% |
| 2008 | -395.55 Thousand USD | -331.94% |
| 2007 | 170.54 Thousand USD | -54.28% |
| 2006 | 373.01 Thousand USD | 28.68% |
| 2005 | 289.88 Thousand USD | 103.98% |
| 2004 | 142.11 Thousand USD | 51.01% |
| 2003 | 94.1 Thousand USD | -4.86% |
| 2002 | 98.91 Thousand USD | 60.74% |
| 2001 | 61.53 Thousand USD | -53.27% |
| 2000 | 131.66 Thousand USD | 959.28% |
| 1999 | 12.43 Thousand USD | 179.77% |
| 1998 | -15.58 Thousand USD | -22.33% |
| 1997 | -12.73 Thousand USD | -117.26% |
| 1996 | 73.79 Thousand USD | 134.18% |
| 1995 | 31.51 Thousand USD | -7.82% |
| 1994 | 34.18 Thousand USD | -19.72% |
| 1993 | 42.57 Thousand USD | 0.0% |
| 1992 | - USD | 0.0% |
| 1991 | - USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | -734 Thousand USD | 16.87% |
| 2024 Q2 | -1.09 Million USD | -48.5% |
| 2023 Q2 | -2.41 Million USD | 33.0% |
| 2023 Q3 | -3.37 Million USD | -39.93% |
| 2023 Q4 | -883 Thousand USD | 73.86% |
| 2023 Q1 | -3.6 Million USD | 89.15% |
| 2023 FY | -10.27 Million USD | -109.18% |
| 2022 FY | 111.99 Million USD | 154.47% |
| 2022 Q4 | -33.22 Million USD | -14.69% |
| 2022 Q3 | -28.96 Million USD | -125.8% |
| 2022 Q1 | -71.81 Million USD | -67.16% |
| 2022 Q2 | 112.28 Million USD | 256.35% |
| 2021 Q3 | -47.42 Million USD | -11.18% |
| 2021 Q2 | -42.65 Million USD | -8.3% |
| 2021 Q1 | -39.38 Million USD | 6.43% |
| 2021 Q4 | -42.96 Million USD | 9.41% |
| 2021 FY | -205.6 Million USD | 3.34% |
| 2020 FY | -212.7 Million USD | -8.51% |
| 2020 Q1 | -56.84 Million USD | -15.0% |
| 2020 Q2 | -51.97 Million USD | 8.57% |
| 2020 Q3 | -32.61 Million USD | 37.26% |
| 2020 Q4 | -42.08 Million USD | -29.06% |
| 2019 Q1 | -39.5 Million USD | -0.29% |
| 2019 Q3 | -31.96 Million USD | 42.13% |
| 2019 FY | -196.02 Million USD | -47.81% |
| 2019 Q2 | -55.23 Million USD | -39.82% |
| 2019 Q4 | -49.43 Million USD | -54.65% |
| 2018 Q4 | -39.39 Million USD | -10.63% |
| 2018 Q2 | -33.21 Million USD | -36.13% |
| 2018 Q1 | -24.4 Million USD | -13.88% |
| 2018 Q3 | -35.6 Million USD | -7.18% |
| 2018 FY | -132.61 Million USD | -72.4% |
| 2017 Q2 | -19.67 Million USD | 6.99% |
| 2017 FY | -76.92 Million USD | 14.41% |
| 2017 Q4 | -21.42 Million USD | -46.12% |
| 2017 Q3 | -14.66 Million USD | 25.47% |
| 2017 Q1 | -21.15 Million USD | 7.36% |
| 2016 Q1 | -20.92 Million USD | -19.71% |
| 2016 Q2 | -21.09 Million USD | -0.79% |
| 2016 Q3 | -25.01 Million USD | -18.59% |
| 2016 Q4 | -22.83 Million USD | 8.71% |
| 2016 FY | -89.87 Million USD | -5.64% |
| 2015 Q2 | -27.22 Million USD | -30.31% |
| 2015 FY | -85.07 Million USD | -56.92% |
| 2015 Q4 | -17.48 Million USD | 10.22% |
| 2015 Q3 | -19.47 Million USD | 28.48% |
| 2015 Q1 | -20.89 Million USD | -28.17% |
| 2014 FY | -54.21 Million USD | -90.78% |
| 2014 Q2 | -10.89 Million USD | -18.69% |
| 2014 Q3 | -17.83 Million USD | -63.61% |
| 2014 Q1 | -9.18 Million USD | -9.6% |
| 2014 Q4 | -16.3 Million USD | 8.58% |
| 2013 FY | -28.41 Million USD | 19.08% |
| 2013 Q4 | -8.37 Million USD | -9.2% |
| 2013 Q3 | -7.67 Million USD | -27.68% |
| 2013 Q2 | -6 Million USD | 5.74% |
| 2013 Q1 | -6.37 Million USD | -11.32% |
| 2012 Q3 | -4.25 Million USD | 64.11% |
| 2012 Q4 | -5.72 Million USD | -34.66% |
| 2012 Q2 | -11.85 Million USD | 10.83% |
| 2012 Q1 | -13.28 Million USD | 0.76% |
| 2012 FY | -35.12 Million USD | -171.97% |
| 2011 Q3 | -78.53 Thousand USD | -37.6% |
| 2011 FY | -12.91 Million USD | -1757.04% |
| 2011 Q1 | 613.44 Thousand USD | 663.58% |
| 2011 Q2 | -57.07 Thousand USD | -109.3% |
| 2011 Q4 | -13.39 Million USD | -16952.35% |
| 2010 Q2 | -269.08 Thousand USD | 22.54% |
| 2010 Q4 | -108.84 Thousand USD | -463.42% |
| 2010 Q3 | 29.95 Thousand USD | 111.13% |
| 2010 Q1 | -347.39 Thousand USD | 44.97% |
| 2010 FY | -695.37 Thousand USD | 57.97% |
| 2009 Q2 | -14.16 Thousand USD | 51.2% |
| 2009 FY | -1.65 Million USD | -318.29% |
| 2009 Q3 | -491.26 Thousand USD | -3367.15% |
| 2009 Q4 | -631.31 Thousand USD | -28.51% |
| 2009 Q1 | -29.03 Thousand USD | -143.93% |
| 2008 Q1 | -32.68 Thousand USD | 22.58% |
| 2008 FY | -395.55 Thousand USD | -331.94% |
| 2008 Q3 | -46.5 Thousand USD | 84.73% |
| 2008 Q2 | -304.46 Thousand USD | -831.63% |
| 2008 Q4 | -11.9 Thousand USD | 74.41% |
| 2007 Q3 | 92.93 Thousand USD | 40.93% |
| 2007 FY | 170.54 Thousand USD | -54.28% |
| 2007 Q4 | -42.21 Thousand USD | -145.42% |
| 2007 Q2 | 65.94 Thousand USD | 21.29% |
| 2007 Q1 | 54.37 Thousand USD | -33.48% |
| 2006 Q1 | 57.8 Thousand USD | -37.59% |
| 2006 Q3 | 154.15 Thousand USD | 96.83% |
| 2006 FY | 373.01 Thousand USD | 28.68% |
| 2006 Q4 | 81.73 Thousand USD | -46.98% |
| 2006 Q2 | 78.31 Thousand USD | 35.48% |
| 2005 Q1 | 76.15 Thousand USD | -9.7% |
| 2005 Q2 | 9355.00 USD | -87.72% |
| 2005 FY | 289.88 Thousand USD | 103.98% |
| 2005 Q3 | 111.76 Thousand USD | 1094.69% |
| 2005 Q4 | 92.61 Thousand USD | -17.13% |
| 2004 Q4 | 84.32 Thousand USD | 53.94% |
| 2004 Q1 | -24.66 Thousand USD | -186.59% |
| 2004 Q2 | 27.67 Thousand USD | 212.18% |
| 2004 Q3 | 54.78 Thousand USD | 97.97% |
| 2004 FY | 142.11 Thousand USD | 51.01% |
| 2003 Q2 | 12.34 Thousand USD | 11.71% |
| 2003 FY | 94.1 Thousand USD | -4.86% |
| 2003 Q4 | 28.48 Thousand USD | -32.54% |
| 2003 Q3 | 42.22 Thousand USD | 242.05% |
| 2003 Q1 | 11.05 Thousand USD | -69.35% |
| 2002 Q4 | 36.05 Thousand USD | 53.98% |
| 2002 Q1 | 22.81 Thousand USD | 201.79% |
| 2002 Q2 | 16.62 Thousand USD | -27.15% |
| 2002 FY | 98.91 Thousand USD | 60.74% |
| 2002 Q3 | 23.41 Thousand USD | 40.87% |
| 2001 Q2 | 32.03 Thousand USD | -18.46% |
| 2001 Q1 | 39.29 Thousand USD | -43.01% |
| 2001 FY | 61.53 Thousand USD | -53.27% |
| 2001 Q4 | -22.41 Thousand USD | -277.65% |
| 2001 Q3 | 12.61 Thousand USD | -60.62% |
| 2000 Q3 | 36.75 Thousand USD | 144.45% |
| 2000 Q2 | 15.03 Thousand USD | 37.55% |
| 2000 Q1 | 10.93 Thousand USD | 888.6% |
| 2000 FY | 131.66 Thousand USD | 959.28% |
| 2000 Q4 | 68.95 Thousand USD | 87.62% |
| 1999 Q1 | -7433.00 USD | 0.0% |
| 1999 Q3 | 11.83 Thousand USD | 25.81% |
| 1999 Q2 | 9410.00 USD | 226.6% |
| 1999 FY | 12.43 Thousand USD | 179.77% |
| 1999 Q4 | -1386.00 USD | -111.71% |
| 1998 FY | -15.58 Thousand USD | -22.33% |
| 1997 FY | -12.73 Thousand USD | -117.26% |
| 1996 FY | 73.79 Thousand USD | 134.18% |
| 1995 FY | 31.51 Thousand USD | -7.82% |
| 1994 FY | 34.18 Thousand USD | -19.72% |
| 1993 FY | 42.57 Thousand USD | 0.0% |
| 1992 FY | - USD | 0.0% |
| 1991 FY | - USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Collegium Pharmaceutical, Inc. | 48.15 Million USD | 121.344% |
| Embecta Corp. | 70.4 Million USD | 114.599% |
| ANI Pharmaceuticals, Inc. | 18.77 Million USD | 154.731% |
| Dynavax Technologies Corporation | -6.38 Million USD | -60.87% |
| Esperion Therapeutics, Inc. | -209.24 Million USD | 95.088% |
| Pacira BioSciences, Inc. | 41.95 Million USD | 124.498% |
| PainReform Ltd. | -9.34 Million USD | -9.996% |
| Aquestive Therapeutics, Inc. | -7.87 Million USD | -30.597% |
| Sunshine Biopharma, Inc. | -4.5 Million USD | -128.094% |
| SCYNEXIS, Inc. | 67.04 Million USD | 115.331% |
| China SXT Pharmaceuticals, Inc. | -3.09 Million USD | -231.705% |
| Cosmos Health Inc. | -18.54 Million USD | 44.571% |
| Journey Medical Corporation | -3.85 Million USD | -166.753% |
| Sunshine Biopharma, Inc. | -4.5 Million USD | -128.094% |
| Safety Shot Inc | -15.08 Million USD | 31.857% |
| Alpha Teknova, Inc. | -36.78 Million USD | 72.055% |
| Intra-Cellular Therapies, Inc. | -139.67 Million USD | 92.641% |
| Bright Green Corporation | -13.12 Million USD | 21.707% |
| Procaps Group, S.A. | 42.54 Million USD | 124.161% |
| Theratechnologies Inc. | -23.95 Million USD | 57.098% |
| Harrow Health, Inc. | -24.41 Million USD | 57.896% |
| Sonoma Pharmaceuticals, Inc. | -4.83 Million USD | -112.575% |
| Biofrontera Inc. | -20.13 Million USD | 48.944% |
| DURECT Corporation | -27.62 Million USD | 62.793% |
| Supernus Pharmaceuticals, Inc. | 1.31 Million USD | 881.003% |
| Cronos Group Inc. | -73.96 Million USD | 86.104% |
| OptiNose, Inc. | -35.48 Million USD | 71.034% |
| Ironwood Pharmaceuticals, Inc. | -1 Billion USD | 98.974% |
| Kala Pharmaceuticals, Inc. | -42.19 Million USD | 75.644% |
| RedHill Biopharma Ltd. | 23.91 Million USD | 142.975% |
| Organogenesis Holdings Inc. | 4.94 Million USD | 307.846% |
| Guardion Health Sciences, Inc. | 158.03 Thousand USD | 6603.705% |
| Cumberland Pharmaceuticals Inc. | -6.27 Million USD | -63.68% |
| Radius Health, Inc. | -25.79 Million USD | 60.149% |
| Universe Pharmaceuticals INC | -6.16 Million USD | -66.768% |
| ProPhase Labs, Inc. | -16.78 Million USD | 38.756% |
| Phibro Animal Health Corporation | 2.41 Million USD | 525.414% |
| Procaps Group S.A. | 42.54 Million USD | 124.161% |
| Alvotech | -551.73 Million USD | 98.137% |
| Viatris Inc. | 54.7 Million USD | 118.79% |
| Rockwell Medical, Inc. | -8.43 Million USD | -21.792% |
| Aytu BioPharma, Inc. | -15.84 Million USD | 35.13% |
| SIGA Technologies, Inc. | 68.06 Million USD | 115.099% |
| Tilray Brands, Inc. | -244.98 Million USD | 95.805% |
| Lifecore Biomedical, Inc. | 12.01 Million USD | 185.557% |
| Shineco, Inc. | -22.44 Million USD | 54.216% |
| PetIQ, Inc. | 2.13 Million USD | 582.309% |
| Regencell Bioscience Holdings Limited | -4.3 Million USD | -138.921% |
| Incannex Healthcare Limited | -18.45 Million USD | 44.32% |
| Neurocrine Biosciences, Inc. | 249.7 Million USD | 104.116% |
| Alimera Sciences, Inc. | -20.13 Million USD | 48.947% |
| Silver Spike Investment Corp. | 7.34 Million USD | 240.025% |
| Assertio Holdings, Inc. | -331.94 Million USD | 96.904% |
| Shuttle Pharmaceuticals Holdings, Inc. | -6.59 Million USD | -55.899% |
| Petros Pharmaceuticals, Inc. | -8.16 Million USD | -25.907% |
| Clever Leaves Holdings Inc. | -17.89 Million USD | 42.578% |
| Cyclo Therapeutics, Inc. | -20.05 Million USD | 48.757% |
| Avadel Pharmaceuticals plc | -160.27 Million USD | 93.587% |
| Hempacco Co., Inc. | -13.12 Million USD | 21.698% |
| Talphera, Inc. | -18.39 Million USD | 44.132% |
| Alvotech | -551.73 Million USD | 98.137% |
| Eagle Pharmaceuticals, Inc. | 35.64 Million USD | 128.837% |
| Lantheus Holdings, Inc. | 326.66 Million USD | 103.146% |
| Currenc Group, Inc. | -15.3 Million USD | 32.852% |
| Kamada Ltd. | 8.28 Million USD | 224.07% |
| Indivior PLC | 2 Million USD | 613.9% |
| Evoke Pharma, Inc. | -7.79 Million USD | -31.9% |
| Flora Growth Corp. | -57.03 Million USD | 81.98% |
| Cyclo Therapeutics, Inc. | -20.05 Million USD | 48.757% |
| Evolus, Inc. | -61.68 Million USD | 83.338% |
| HUTCHMED (China) Limited | 100.78 Million USD | 110.198% |
| Amphastar Pharmaceuticals, Inc. | 137.54 Million USD | 107.472% |
| Akanda Corp. | -32.27 Million USD | 68.155% |